Thomas C Rowe

Thomas C Rowe, Ph.D.

ASO PROFESSOR

Department: MD-PHARMACOLOGY / THERAPEUTICS
Business Phone: (352) 273-9421
Business Email: tomrowe@ufl.edu

Teaching Profile

Courses Taught
2016-2024
GMS6847 Translational Research and Therapeutics: Bench, Bedside, Community, & Policy
2019-2021
GMS6551 Fundamentals of Medical Pharmacology and Therapeutics
2019-2024
GMS6540 Medical Pharmacology and Therapeutics IV: Cancer, Antimicrobial and Antiparasitic Agents
2018-2021,2023-2024
GMS6560 Molecules to Man: Past, Present and Future Therapeutic Strategies for Disease
2020-2022
PAS5026 Pharmacotherapeu 2
2018,2020-2021
BMS6300 Fund Micro and Immuno
2014-2015,2017-2024
GMS6065 Fundamentals of Cancer Biology
2011-2021
DEN6262 Prin of Pharmacology
2015-2016,2018-2021,2020-2024
GMS6009 Principles of Drug Action and Therapeutics
2010,2012-2014,2014-2019,2017-2023,2019-2024,2021-2024
GMS6053 Cancer Biology and Therapeutics
2013-2014,2019-2023,2021-2024,2023-2024
BMS6031 Foundations of Med
2018
GMS7980 Research for Doctoral Dissertation
2015-2017
GMS6003 Fundamentals of Graduate Research and Professional Development
2014,2016-2022,2022
MDU4002 Introduction to Medical Science Seminar 2
2015
GMS6090 Research in Medical Sciences
2015
BMS4905 Medical Sciences Senior Research
2011-2013
BMS6404 Pharmacology
2021,2024
GMS6895 CTS Journal Club
2024
BMS6632 Endo and Reproduction

Research Profile

The Rowe Lab is interested in the cellular function of nuclear and organellar DNA topoisomerases and their role as targets for cancer and malarial chemotherapy. DNA topoisomerases are an ubiquitous class of enzymes that regulate the structure and function of cellular chromosomes. These enzymes are also targets of important anticancer (e.g., anthracyclines, epipodophyllotoxins, amsacrines, and camptothecins) and antimicrobial (fluoroquinolone) drugs. Most recently, the lab’s efforts have focused on the identification of a type II topoisomerase that is associated with the novel 35 kb circular plastid DNA of the malarial parasite P. falciparum. The 35 kb plastid DNA is thought to be localized within the apicoplast, a non-photosynthetic plastid an organelle of unknown function which has no counterpart in mammalian cells. Pharmacologic and genetic evidence indicate that the topoisomerase activity associated with the 35 kb plastid DNA is related to the bacterial type II topoisomerase DNA gyrase. The lab is currently investigating whether this novel topoisomerase might provide a selective target for the development of new antimalarial drugs. They are also interested in identifying the role of this unusual topoisomerase in the regulation of the novel 35 kb plastid genome of malaria.

Publications

2013
Assembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes.
Biochemistry. 52(20):3489-501 [DOI] 10.1021/bi400047u. [PMID] 23627734.
2010
Novel Drug Targets To Overcome De Novo Drug-Resistance in Multiple Myeloma
Blood. 116
2009
A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.
The Journal of biological chemistry. 284(43):29945-55 [DOI] 10.1074/jbc.M109.055251. [PMID] 19710018.
2009
Blocking a Topoisomerase II Alpha Nuclear Export Signal Sensitizes Human Multiple Myeloma Cells To Topoisomerase II Inhibitors.
Blood. 114
2009
Genetic analysis of avian influenza A viruses isolated from domestic waterfowl in live-bird markets of Hanoi, Vietnam, preceding fatal H5N1 human infections in 2004.
Archives of virology. 154(8):1249-61 [DOI] 10.1007/s00705-009-0429-2. [PMID] 19578928.
2008
Cloning, expression and immunoassay detection of ferret IFN-gamma.
Developmental and comparative immunology. 32(8):890-7 [DOI] 10.1016/j.dci.2007.12.008. [PMID] 18262264.
2007
Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening.
Antimicrobial agents and chemotherapy. 51(10):3688-98 [PMID] 17682095.
2006
Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
Cancer research. 66(2):1070-80 [PMID] 16424043.
2005
Expression and characterization of the ATP-binding domain of a malarial Plasmodium vivax gene homologous to the B-subunit of the bacterial topoisomerase DNA gyrase.
Molecular and biochemical parasitology. 140(1):107-17 [PMID] 15694492.
2005
Induction of petite mutants in yeast Saccharomyces cerevisiae by the anticancer drug dequalinium.
Mutation research. 572(1-2):84-97 [PMID] 15790492.
2002
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Leukemia & lymphoma. 43(5):989-99 [PMID] 12148910.
2001
Isolation of covalent enzyme-DNA complexes.
Methods in molecular biology (Clifton, N.J.). 95:129-35 [PMID] 11089226.
2001
Mitochondrial DNA metabolism targeting drugs.
Advanced drug delivery reviews. 49(1-2):175-87 [PMID] 11377810.
1999
Analysis of Plasmodium falciparum mitochondrial six-kilobase DNA by pulse-field electrophoresis.
The Journal of parasitology. 85(2):386-9 [PMID] 10219329.
1998
Dequalinium induces a selective depletion of mitochondrial DNA from HeLa human cervical carcinoma cells.
Experimental cell research. 245(1):137-45 [PMID] 9828109.
1998
DQAsomes: a novel potential drug and gene delivery system made from Dequalinium.
Pharmaceutical research. 15(2):334-7 [PMID] 9523323.
1997
Topoisomerase II inhibitors induce cleavage of nuclear and 35-kb plastid DNAs in the malarial parasite Plasmodium falciparum.
DNA and cell biology. 16(12):1483-92 [PMID] 9428797.
1996
Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells.
Molecular pharmacology. 50(5):1178-88 [PMID] 8913349.
1994
Analysis of expressed sequence tags from Plasmodium falciparum.
Molecular and biochemical parasitology. 66(1):97-104 [PMID] 7984191.
1993
4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells.
Journal of cellular biochemistry. 51(2):165-74 [PMID] 8440750.
1993
Analysis of topoisomerase II-mediated DNA cleavage in the 5′-region of the Drosophila hsp70 gene. Identification of a novel half-site DNA substrate for topoisomerase II cleavage.
The Journal of biological chemistry. 268(22):16449-57 [PMID] 8393863.
1993
Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
Molecular pharmacology. 43(2):207-16 [PMID] 8094226.
1992
Analysis of topoisomerase I and II cleavage sites on the Drosophila actin and Hsp70 heat shock genes.
Biochemistry. 31(9):2492-501 [PMID] 1312349.
1991
Phosphorylation of DNA topoisomerase II in a human tumor cell line.
The Journal of biological chemistry. 266(12):7957-61 [PMID] 1850428.
1990
Drug sensitivity of heat-resistant mouse B16 melanoma variants.
Radiation research. 124(1):15-21 [PMID] 2236492.
1989
Interaction of topoisomerase 1 with the transcribed region of the Drosophila HSP 70 heat shock gene.
Nucleic acids research. 17(21):8495-509 [PMID] 2555773.
1989
Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line.
Biochemistry. 28(13):5680-7 [PMID] 2550059.
1989
Specific interactions of histone H1 and a 45 kilodalton nuclear protein with a putative matrix attachment site in the distal promoter region of a cell cycle-regulated human histone gene.
Journal of cellular physiology. 139(2):320-8 [PMID] 2715190.
1987
Camptothecin inhibits hsp 70 heat-shock transcription and induces DNA strand breaks in hsp 70 genes in Drosophila.
NCI monographs : a publication of the National Cancer Institute. (4):49-53 [PMID] 2819731.
1986
DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.
Cancer research. 46(4 Pt 2):2021-6 [PMID] 3004716.
1986
In vivo localization of DNA topoisomerase II cleavage sites on Drosophila heat shock chromatin.
Molecular and cellular biology. 6(4):985-92 [PMID] 3023886.
1986
Topoisomerase from Ustilago maydis forms a covalent complex with single-stranded DNA through a phosphodiester bond to tyrosine.
Biochemistry. 25(23):7362-8 [PMID] 3026452.
1985
Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells.
Cancer research. 45(11 Pt 2):5872-6 [PMID] 2996763.
1985
In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatin.
Cell. 41(1):127-32 [PMID] 2986841.
1985
Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage.
Biochemical pharmacology. 34(14):2483-7 [PMID] 2990488.
1984
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.
Science (New York, N.Y.). 226(4673):466-8 [PMID] 6093249.
1984
Identification of the breakage-reunion subunit of T4 DNA topoisomerase.
The Journal of biological chemistry. 259(14):9177-81 [PMID] 6086624.
1984
Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
The Journal of biological chemistry. 259(21):13560-6 [PMID] 6092381.
1984
Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.
Cancer research. 44(12 Pt 1):5857-60 [PMID] 6094001.
1983
Cleavage of DNA by mammalian DNA topoisomerase II.
The Journal of biological chemistry. 258(24):15365-70 [PMID] 6317692.

Grants

Jul 2006 – Dec 2020
21st Century Research & Economic Development Investment Program (REDIP)
Role: Project Manager
Funding: STATE UNIV SYS OF FL BOARD OF GOVERNORS

Contact Details

Phones:
Business:
(352) 273-9421
Emails:
Business:
tomrowe@ufl.edu
Addresses:
Business Mailing:
PO Box 100267
GAINESVILLE FL 32610
Business Street:
R5-224 ARB
GAINESVILLE FL 32610